ArticleMolecular cancer2014
Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture.
Article in Molecular cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Polydopamine-Coated Surfaces Promote Adhesion, Migration, Proliferation, Chemoresistance, Stemness, and Epithelial-Mesenchymal Transition of Human Prostate Cancer Cell Lines In Vitro via Integrin αInternational journal of molecular sciences · 2026Article
- A Naturally Occurring Urinary Collagen Type I Alpha 1-Derived Peptide Inhibits Collagen Type I-Induced Endothelial Cell Migration at Physiological Concentrations.International journal of molecular sciences · 2025Article
- Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).Oncology reports · 2025Review
- A novel perspective on bone tumors: advances in organoid research.Frontiers in pharmacology · 2025Review
- JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4.Theranostics · 2025Article
- Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).International journal of oncology · 2024Review
- Review
- The role of integrin family in bone metabolism and tumor bone metastasis.Cell death discovery · 2023Review
- IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.Bosnian journal of basic medical sciences · 2022Article
- E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy.Journal of clinical medicine · 2021Article
- Review
- Article
- 3D Co-culture System of Mouse Prostatic Wild-type Fibroblasts withHuman Prostate Cancer Epithelial Cells.Bio-protocol · 2019Article
- Integrin α2β1 decelerates proliferation, but promotes survival and invasion of prostate cancer cells.Oncotarget · 2018Article
- Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics.Translational andrology and urology · 2015Review
- Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance.Trends in cell biology · 2015Review
- The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Frontiers in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundProstate cancer (PCa) bone metastasis can be markedly enhanced by increased receptor activator of NF kappa-B ligand (RANKL) expression in PCa cells. Molecular mechanisms that account for the increased predilection of PCa for bone include increased bone turnover, promotion of PCa cell growth and survival in the bone environment, and recruitment of bystander dormant cells to participate in bone metastasis. The current study tests the hypothesis that PCa cells acquire high adhesion to bone matrix proteins, which controls PCa bone colonization, under the RANKL/RANK and AR axes.
methodsWe used a highly bone metastatic RANKL-overexpressing LNCaP PCa cell line, LNCaP(RANKL), as a model to pursue the molecular mechanisms underlying the increased adhesion of PCa cells to collagens. A three-dimensional (3-D) suspension PCa organoid model was developed. The functions of integrin α2 in cell adhesion and survival were evaluated by flow cytometry and western blot. AR expression and functionality were compared in 2-D monolayer versus 3-D suspension cultures using AR promoter- and PSA promoter-luciferase activity. AR role in cell adhesion was assessed using an adhesion assay.
resultsLNCaP(RANKL) cells were shown to adhere tightly to ColI matrix through increased α2 integrin expression. This increased adhesion, concomitant with activation of the FAK and Akt pathways, was further enhanced by culturing LNCaP(RANKL) cells in 3-D suspension. Under the influence of 3-D suspension culture, AR was restored in LNCaP(RANKL) cells via downregulation of AP-4 transcription factor, and supported increased α2 integrin expression and adhesion to ColI.
conclusion3-D suspension culture and in vivo PCa tumor growth restore AR through downregulation of AP-4, enhancing integrin α2 expression and adhesion to ColI which is rich in bone matrices. The interactions of PCa with ColI, mediated by integrin α2 and AR expression, could be a key molecular event accounting for PCa bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.